Published in Brain on April 01, 2003
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain (2010) 3.48
Evidence for a two-stage disability progression in multiple sclerosis. Brain (2010) 2.63
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol (2005) 2.44
Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol (2012) 2.32
Impact of multiple sclerosis relapses on progression diminishes with time. Neurology (2009) 1.86
IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis. Sci Transl Med (2011) 1.73
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler (2012) 1.59
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest (2005) 1.41
XY sex chromosome complement, compared with XX, in the CNS confers greater neurodegeneration during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2014) 1.39
Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol (2009) 1.27
Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol (2012) 1.25
Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One (2014) 1.24
Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx (2004) 1.23
A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain (2012) 1.22
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol (2013) 1.18
Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol (2009) 1.18
Estimating Time to Event From Longitudinal Categorical Data: An Analysis of Multiple Sclerosis Progression. J Am Stat Assoc (2007) 1.18
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol (2013) 1.17
Sex differences in autoimmune diseases. Biol Sex Differ (2011) 1.16
Contribution of relapses to disability in multiple sclerosis. J Neurol (2008) 1.15
Age and disability accumulation in multiple sclerosis. Neurology (2011) 1.15
Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry. J Neurol Sci (2009) 1.11
Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis. Mult Scler (2008) 1.06
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol (2013) 1.06
Epigenetic changes in patients with multiple sclerosis. Nat Rev Neurol (2012) 1.05
The path to self-management: a qualitative study involving older people with multiple sclerosis. Physiother Can (2012) 1.05
Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology (2009) 1.04
Neurological functional recovery after thymosin beta4 treatment in mice with experimental auto encephalomyelitis. Neuroscience (2009) 1.03
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. J Neurol Neurosurg Psychiatry (2007) 1.02
Clinical characteristics of patients with late-onset multiple sclerosis. J Neurol (2008) 0.99
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol (2007) 0.96
European validation of a standardized clinical description of multiple sclerosis. J Neurol (2004) 0.96
Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol (2005) 0.95
Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. Expert Rev Clin Immunol (2014) 0.94
Myelin repair: the role of stem and precursor cells in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci (2008) 0.93
Adult gonadal hormones selectively regulate sexually dimorphic quantitative traits observed in experimental allergic encephalomyelitis. Am J Pathol (2004) 0.93
Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol (2015) 0.92
MRI quantification of gray and white matter damage in patients with early-onset multiple sclerosis. J Neurol (2006) 0.91
Getting the balance right: a randomised controlled trial of physiotherapy and Exercise Interventions for ambulatory people with multiple sclerosis. BMC Neurol (2009) 0.91
A function of myelin is to protect axons from subsequent injury: implications for deficits in multiple sclerosis. Brain (2003) 0.89
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur J Neurol (2015) 0.89
Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol (2009) 0.88
Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One (2013) 0.86
Sex differences in neurodevelopmental and neurodegenerative disorders: Focus on microglial function and neuroinflammation during development. J Steroid Biochem Mol Biol (2015) 0.86
Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol (2007) 0.86
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment. J Neurol (2012) 0.85
Corpus callosum index and long-term disability in multiple sclerosis patients. J Neurol (2010) 0.85
Clinical characteristics and long term prognosis in early onset multiple sclerosis. J Neurol (2006) 0.84
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol (2013) 0.84
The effect of smoking on the symptoms and progression of multiple sclerosis: a review. J Inflamm Res (2010) 0.84
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler (2014) 0.83
Walking impairment in patients with multiple sclerosis: exercise training as a treatment option. Neuropsychiatr Dis Treat (2010) 0.83
Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS. Neurology (2014) 0.82
African ancestry is a predictor factor to secondary progression in clinical course of multiple sclerosis. ISRN Neurol (2012) 0.82
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review. PLoS One (2014) 0.82
Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a review. Mult Scler Int (2011) 0.82
The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: concept, content, and pilot results. Patient Prefer Adherence (2015) 0.81
Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. Mult Scler (2011) 0.80
Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers (2013) 0.80
Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France. J Neurol (2007) 0.80
Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients? Int J Mol Sci (2011) 0.80
Isolated, relapsing and progressive demyelinating diseases of the central nervous system. J Neurol (2008) 0.80
A comparative assessment of cerebral white matter by magnetization transfer imaging in early- and adult-onset multiple sclerosis patients matched for disease duration. J Neurol (2010) 0.80
Personalized medicine in multiple sclerosis: hope or reality? BMC Med (2012) 0.80
Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. PLoS One (2016) 0.79
Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study). J Neurol (2010) 0.79
Two Cases of Acute Disseminated Encephalomyelitis Following Vaccination Against Human Papilloma Virus. Intern Med (2016) 0.79
Lessons for clinical trials from natalizumab in multiple sclerosis. BMJ (2006) 0.79
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurol Ther (2016) 0.79
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PLoS One (2015) 0.79
Predictive value of imaging markers at multiple sclerosis disease onset based on gadolinium- and USPIO-enhanced MRI and machine learning. PLoS One (2014) 0.79
The role of hereditary spastic paraplegia related genes in multiple sclerosis. A study of disease susceptibility and clinical outcome. J Neurol (2007) 0.78
Segmented corpus callosum diffusivity correlates with the Expanded Disability Status Scale score in the early stages of relapsing-remitting multiple sclerosis. Clinics (Sao Paulo) (2013) 0.78
Predictors of disability worsening in clinically isolated syndrome. Ann Clin Transl Neurol (2015) 0.78
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurol Sci (2012) 0.78
The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset. J Neurol (2015) 0.78
Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol (2016) 0.78
Geographic variations of multiple sclerosis prevalence in France: The latitude gradient is not uniform depending on the socioeconomic status of the studied population. Mult Scler J Exp Transl Clin (2016) 0.78
Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis. J Neurol (2006) 0.77
The retrovirus/superantigen hypothesis of multiple sclerosis. Cell Mol Neurobiol (2014) 0.77
Treatment trials in progressive MS--current challenges and future directions. Nat Rev Neurol (2013) 0.77
H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes. Ther Adv Chronic Dis (2016) 0.77
When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults? Mult Scler Int (2011) 0.77
Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy. Neurol Sci (2011) 0.76
Multiple sclerosis: Mechanisms of disability accumulation in multiple sclerosis. Nat Rev Neurol (2010) 0.76
Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology (2015) 0.76
Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment. Mult Scler (2011) 0.76
Gender effect on neurodegeneration and myelin markers in an animal model for multiple sclerosis. BMC Neurosci (2012) 0.76
17beta-estradiol protects male mice from cuprizone-induced demyelination and oligodendrocyte loss. Neurobiol Dis (2010) 0.76
Cortical excitability changes over time in progressive multiple sclerosis. Funct Neurol (2016) 0.75
Effect of catalpol on remyelination through experimental autoimmune encephalomyelitis acting to promote Olig1 and Olig2 expressions in mice. BMC Complement Altern Med (2017) 0.75
Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials. Mult Scler Relat Disord (2016) 0.75
Exploration of machine learning techniques in predicting multiple sclerosis disease course. PLoS One (2017) 0.75
A study of patients with aggressive multiple sclerosis at disease onset. Neuropsychiatr Dis Treat (2016) 0.75
Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald Criteria. ISRN Neurol (2012) 0.75
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. BMC Neurol (2009) 0.75
Selected health behaviors moderate the progression of functional limitations in persons with multiple sclerosis: Eleven years of annual follow-up. Disabil Health J (2016) 0.75
Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study. J Neurol (2016) 0.75
Natural history of multiple sclerosis: a unifying concept. Brain (2006) 2.96
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology (2013) 2.59
Age at disability milestones in multiple sclerosis. Brain (2006) 2.37
Natural history of multiple sclerosis with childhood onset. N Engl J Med (2007) 1.89
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain (2004) 1.70
Quantitative study of nerves of the human left atrium. Heart Rhythm (2005) 1.59
QT dynamicity and sudden death after myocardial infarction: results of a long-term follow-up study. J Cardiovasc Electrophysiol (2003) 1.56
Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic significance of an insular component. Am J Surg Pathol (2002) 1.46
Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol (2003) 1.40
Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol (2010) 1.28
Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: a study of 157 cases. Stroke (2004) 1.25
Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. J Clin Oncol (2004) 1.24
Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator. J Neurol Sci (2004) 1.24
Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis (2004) 1.19
Factors influencing early admission in a French stroke unit. Stroke (2002) 1.16
Predictive value of sensory and cognitive evoked potentials for awakening from coma. Neurology (2004) 1.14
NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler (2008) 1.12
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain (2011) 1.11
Geographic variations of multiple sclerosis in France. Brain (2010) 1.10
Unusual monocular pendular nystagmus in multiple sclerosis. J Neuroophthalmol (2011) 1.06
Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg (2006) 1.02
The influence of glenohumeral prosthetic mismatch on glenoid radiolucent lines: results of a multicenter study. J Bone Joint Surg Am (2002) 1.02
Ethical issues of informed consent in acute stroke. Analysis of the modalities of consent in 56 patients enrolled in urgent therapeutic trials. Cerebrovasc Dis (2005) 1.01
Uveitis associated with multiple sclerosis. Mult Scler (2008) 0.98
Glenohumeral arthrosis in anterior instability before and after surgical treatment: incidence and contributing factors. Am J Sports Med (2004) 0.97
The clinical epidemiology of multiple sclerosis. Neuroimaging Clin N Am (2008) 0.97
European validation of a standardized clinical description of multiple sclerosis. J Neurol (2004) 0.96
Prevention of implantable defibrillator shocks by cognitive behavioral therapy: a pilot trial. Am Heart J (2006) 0.95
The natural history of multiple sclerosis with childhood onset. Clin Neurol Neurosurg (2008) 0.92
Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases. Brain (2009) 0.90
Natural history of multiple sclerosis: implications for counselling and therapy. Curr Opin Neurol (2002) 0.90
Evolution of lesion volume in acute stroke treated by intravenous t-PA. J Magn Reson Imaging (2005) 0.89
Steroid hormones in multiple sclerosis. J Neurol Sci (2005) 0.89
Combined central retinal arterial and venous obstruction: emergency ophthalmic arterial fibrinolysis. Radiology (2002) 0.87
Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry (2012) 0.87
Hypointense transcerebral veins at T2*-weighted MRI: a marker of hemorrhagic transformation risk in patients treated with intravenous tissue plasminogen activator. J Cereb Blood Flow Metab (2003) 0.86
Early magnetic resonance imaging prediction of arterial recanalization and late infarct volume in acute carotid artery stroke. J Cereb Blood Flow Metab (2003) 0.85
Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J Hepatol (2005) 0.85
Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability. Mult Scler (2013) 0.84
Late auditory and event-related potentials can be useful to predict good functional outcome after coma. Arch Phys Med Rehabil (2005) 0.84
Evidence for deficiencies in perceptual and semantic olfactory processes in Parkinson's disease. Chem Senses (2003) 0.83
[The natural history of multiple sclerosis]. Rev Prat (2006) 0.83
[Multiple sclerosis: a degenerative disease?]. Bull Acad Natl Med (2008) 0.79
Leukodystrophy with a cerebellar cystic aspect and intracranial atherosclerosis: an atypical presentation of cerebrotendinous xanthomatosis. J Neurol (2011) 0.79
Non-specific immunosuppressants in the treatment of multiple sclerosis. Clin Neurol Neurosurg (2004) 0.78
[Plasma exchanges in severe and acute inflammatory demyelinating attacks of the central nervous system]. Presse Med (2011) 0.77
[Risk factors for secondary retinal detachment after extraction of intraocular foreign bodies]. Can J Ophthalmol (2002) 0.77
Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications. Ther Adv Neurol Disord (2010) 0.77
Quantitative measurements of regional lung ventilation using helium-3 MRI in a methacholine-induced bronchoconstriction model. J Magn Reson Imaging (2006) 0.77
Myopathic camptocormia associated with myasthenia gravis. Clin Neurol Neurosurg (2012) 0.75
Abdominal CT angiography before surgery as a predictor of postoperative death in acute aortic dissection. AJR Am J Roentgenol (2004) 0.75
[Multiple sclerosis (MS), an inflammatory or degenerative disease?]. Presse Med (2004) 0.75
[Cytoimmunological profile of cerebrospinal fluid in diagnosis of multiple sclerosis]. Pathol Biol (Paris) (2005) 0.75
Christian Confavreux (1949 - 2013). Mult Scler (2013) 0.75
[Autoimmune hepatitis associated with multiple sclerosis]. Gastroenterol Clin Biol (2004) 0.75
[New therapies in multiple sclerosis]. Rev Prat (2012) 0.75
Magnetic resonance imaging: significance of early ischemic changes on computed tomography. Cerebrovasc Dis (2004) 0.75
Clinical and radiological characteristics in multiple sclerosis patients with large cavitary lesions. Eur Neurol (2012) 0.75
Neuromyelitis optica and neuromyelitis optica spectrum disorders. Curr Opin Neurol (2017) 0.75
Standardized MR protocol for the evaluation of MRA sequences and/or contrast agents effects in high-degree arterial stenosis analysis. MAGMA (2002) 0.75